Diversified Portfolio Fortress Biotech maintains a portfolio of eight marketed prescription products and multiple development programs across oncology, dermatology, and rare diseases, offering multiple collaboration and licensing opportunities with potential buyers or partners seeking a diversified biopharma pipeline.

Strategic Partnerships The company has established active collaborations with top research institutions and pharma players (AstraZeneca, City of Hope, Fred Hutch, Dana-Farber, Columbia, NIH) which signals openness to co-development, milestone-based deals, and strategic equity or royalty arrangements.

AI and Discovery Recent integration with Partex NV to leverage AI in drug discovery suggests opportunities for BD conversations around AI-enabled asset sourcing, faster go/no-go decisions, and joint exploration of novel targets with reduced development timelines.

Public Market Presence As a Nasdaq-listed entity with active conference participation, Fortress Biotech regularly engages investors and potential partners; potential sales angles include licensing discussions, asset acquisitions, or revenue-sharing models highlighted during investor events.

Clinical and Research Ties Collaboration with NIH on gene therapy programs like AAV-ATP7A for Menkes Syndrome indicates a pathway for translational partnerships, out-licensing rare-disease programs, or co-funding opportunities for advanced gene therapy assets.